EGFR and non-small cell lung carcinoma: Disappointingly, the results of another phase III trial comparing first and second-generation EGFR-TKIs in the second/third-line setting (ARCHER 1009: dacomitinib vs. erlotinib) do not support the greater clinical efficacy of the newer EGFR-TKIs in unselected patients with advanced NSCLC (55).